Athira Pharma, Inc. (NASDAQ:ATHA) Shares Bought by Clarius Group LLC

Clarius Group LLC raised its position in Athira Pharma, Inc. (NASDAQ:ATHA) by 35.8% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 53,551 shares of the company’s stock after buying an additional 14,124 shares during the quarter. Clarius Group LLC owned about 0.14% of Athira Pharma worth $130,000 as of its most recent filing with the SEC.

Several other institutional investors also recently bought and sold shares of ATHA. Point72 Asset Management L.P. acquired a new position in Athira Pharma in the 2nd quarter valued at $2,671,000. Dimensional Fund Advisors LP increased its stake in Athira Pharma by 1,200.2% in the 1st quarter. Dimensional Fund Advisors LP now owns 349,499 shares of the company’s stock valued at $874,000 after buying an additional 322,618 shares during the period. Jacobs Levy Equity Management Inc. acquired a new position in Athira Pharma in the 3rd quarter valued at $748,000. Two Sigma Advisers LP grew its stake in shares of Athira Pharma by 229.0% during the 3rd quarter. Two Sigma Advisers LP now owns 347,400 shares of the company’s stock worth $1,032,000 after purchasing an additional 241,800 shares during the period. Finally, Renaissance Technologies LLC acquired a new position in shares of Athira Pharma during the 3rd quarter worth $698,000. 57.12% of the stock is owned by institutional investors and hedge funds.

Athira Pharma Stock Down 15.6 %

NASDAQ:ATHA opened at $2.06 on Tuesday. Athira Pharma, Inc. has a fifty-two week low of $1.33 and a fifty-two week high of $4.30. The stock has a market cap of $78.96 million, a PE ratio of -0.67 and a beta of 2.78. The firm’s fifty day simple moving average is $3.08 and its 200-day simple moving average is $2.46.

Athira Pharma (NASDAQ:ATHA) last posted its quarterly earnings results on Thursday, February 22nd. The company reported ($0.71) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.96) by $0.25. Equities analysts anticipate that Athira Pharma, Inc. will post -2.86 earnings per share for the current year.

About Athira Pharma

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is ATH-1017 Fosgonimeton, a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.